Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To investigate whether a single intralesional injection of CCH during the Acute Phase of Peyronie's Disease could limit the progression of the disorder by reducing penile curvature and ameliorating penile pain during sexual intercourse.

Next Previous
Search
Trial Profile

To investigate whether a single intralesional injection of CCH during the Acute Phase of Peyronie's Disease could limit the progression of the disorder by reducing penile curvature and ameliorating penile pain during sexual intercourse.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Collagenase clostridium histolyticum (Primary)
  • Indications Peyronie's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Jul 2020 Preliminary results presented at the 35th Congress of the European Association of Urology
    • 05 May 2020 New trial record
    • 27 Apr 2020 Preliminary results published in the Clinical Drug Investigation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top